Antibe Therapeutics Inc(Pre-Merger) ATBPF

RE:RE:RE:ADvices from most-blocked, PoorOpinion!

[Jefferam1]

https://www.antibethera.com/wordpress/wp-content/uploads/2018/08/Antibe-Phase-2B-Study-Review.pdf
Liver-related effects comparable to existing NSAIDs Blood levels of liver enzymes (including alanine transaminase (ALT) and aspartate transaminase (AST)) were measured on days 7 and 14 of treatment and at two-weeks posttreatment (day 28). Over the 14 day treatment course nonclinically significant treatment-related transient elevations in liver transaminases were observed in up to 7% of subjects receiving ATB-346 and up to 7% of subjects receiving naproxen. One subject receiving ATB-346 (0.8%) had clinically significant treatment-related transient transaminase elevations. At the two week post treatment follow up assessment 5.4% of the ATB-346-treated subjects had clinically significant, treatment-related, transient transaminase elevations that had resolved or were resolving. Cumulative data now obtained from three clinical trials in which ATB-346 has been dosed at 250 mg once daily for 10-14 days reveal a 4.7% overall incidence of clinically significant, transient liver transaminase increase; this can be contrasted to diclofenac, the most prescribed NSAID globally, where the incidence of clinically-significant liver transaminase elevations is up to 4%.